Bosentan (under the brand name Tracleer by Actelion Pharmaceuticals) is the first approved endothelian receptor antagonist. It was approved by the FDA in November 2001 and is used in the treatment of Pulmonary Arterial Hypertension.
Provides information on usage, precautions, side effects and brand names when available. Data provided by government agencies and health-related organizations
Features an overview of pulmonary hypertension, prescribing information for US residents, and press releases.
Bosentan Therapy for Pulmonary Arterial Hypertension
Actelion's slide show presentation to the FDA. (August 15, 2001)
Last update:October 17, 2016 at 2:37:04 UTC